Literature DB >> 29401633

Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice.

Marion Adam1, Hanna Heikelä1, Cyril Sobolewski2, Dorothea Portius2, Jenni Mäki-Jouppila1, Arfa Mehmood1,3, Prem Adhikari1, Irene Esposito4, Laura L Elo3, Fu-Ping Zhang1, Suvi T Ruohonen1, Leena Strauss1, Michelangelo Foti2, Matti Poutanen1,5.   

Abstract

Hydroxysteroid (17β) dehydrogenases (HSD17Bs) form an enzyme family characterized by their ability to catalyze reactions in steroid and lipid metabolism. In the present study, we characterized the phenotype of HSD17B13-knockout (HSD17B13KO) mice deficient in Hsd17b13. In these studies, hepatic steatosis was detected in HSD17B13KO male mice, indicated by histologic analysis and by the increased triglyceride concentration in the liver, whereas reproductive performance and serum steroid concentrations were normal in HSD17B13KO mice. In line with these changes, the expression of key proteins in fatty acid synthesis, such as FAS, acetyl-CoA carboxylase 1, and SCD1, was increased in the HSD17B13KO liver. Furthermore, the knockout liver showed an increase in 2 acylcarnitines, suggesting impaired mitochondrial β-oxidation in the presence of unaltered malonyl CoA and AMPK expression. The glucose tolerance did not differ between wild-type and HSD17B13KO mice in the presence of lower levels of glucose 6-phosphatase in HSD17B13KO liver compared with wild-type liver. Furthermore, microgranulomas and increased portal inflammation together with up-regulation of immune response genes were observed in HSD17B13KO mice. Our data indicate that disruption of Hsd17b13 impairs hepatic-lipid metabolism in mice, resulting in liver steatosis and inflammation, but the enzyme does not play a major role in the regulation of reproductive functions.-Adam, M., Heikelä, H., Sobolewski, C., Portius, D., Mäki-Jouppila, J., Mehmood, A., Adhikari, P., Esposito, I., Elo, L. L., Zhang, F.-P., Ruohonen, S. T., Strauss, L., Foti, M., Poutanen, M. Hydroxysteroid (17β) dehydrogenase 13 deficiency triggers hepatic steatosis and inflammation in mice.

Entities:  

Keywords:  lipid droplet; liver; steatohepatitis

Mesh:

Substances:

Year:  2018        PMID: 29401633     DOI: 10.1096/fj.201700914R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.

Authors:  Panu K Luukkonen; Taru Tukiainen; Anne Juuti; Henna Sammalkorpi; P A Nidhina Haridas; Onni Niemelä; Johanna Arola; Marju Orho-Melander; Antti Hakkarainen; Petri T Kovanen; Om Dwivedi; Leif Groop; Leanne Hodson; Amalia Gastaldelli; Tuulia Hyötyläinen; Matej Orešič; Hannele Yki-Järvinen
Journal:  JCI Insight       Date:  2020-03-12

2.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

3.  In vivo stabilization of OPA1 in hepatocytes potentiates mitochondrial respiration and gluconeogenesis in a prohibitin-dependent way.

Authors:  Lingzi Li; Juliette Martin-Levilain; Cecilia Jiménez-Sánchez; Melis Karaca; Michelangelo Foti; Jean-Claude Martinou; Pierre Maechler
Journal:  J Biol Chem       Date:  2019-07-08       Impact factor: 5.157

4.  Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.

Authors:  Carlos J Pirola; Martin Garaycoechea; Diego Flichman; Marco Arrese; Julio San Martino; Carla Gazzi; Gustavo O Castaño; Silvia Sookoian
Journal:  J Lipid Res       Date:  2018-10-15       Impact factor: 5.922

Review 5.  Therapeutic RNA-silencing oligonucleotides in metabolic diseases.

Authors:  Algera Goga; Markus Stoffel
Journal:  Nat Rev Drug Discov       Date:  2022-02-24       Impact factor: 84.694

6.  Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesity.

Authors:  Zhao Zhang; Yu Xun; Shunxing Rong; Lijuan Yan; Jeffrey A SoRelle; Xiaohong Li; Miao Tang; Katie Keller; Sara Ludwig; Eva Marie Y Moresco; Bruce Beutler
Journal:  Nat Commun       Date:  2022-07-16       Impact factor: 17.694

Review 7.  Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

8.  A closer look at the mysterious HSD17B13.

Authors:  X Charlie Dong
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

9.  Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.

Authors:  Wen-Yue Liu; Mohammed Eslam; Kenneth I Zheng; Hong-Lei Ma; Rafael S Rios; Min-Zhi Lv; Gang Li; Liang-Jie Tang; Pei-Wu Zhu; Xiao-Dong Wang; Christopher D Byrne; Giovanni Targher; Jacob George; Ming-Hua Zheng
Journal:  J Clin Transl Hepatol       Date:  2021-02-22

10.  17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.

Authors:  Yanling Ma; Philip M Brown; Dennis D Lin; Jing Ma; Dechun Feng; Olga V Belyaeva; Maren C Podszun; Jason Roszik; Joselyn N Allen; Regina Umarova; David E Kleiner; Natalia Y Kedishvili; Oksana Gavrilova; Bin Gao; Yaron Rotman
Journal:  Hepatology       Date:  2021-03-16       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.